HealthQuad Leads INR 117 Cr Investment in Beta Drugs for Minority Stake The Panchkula-based pharmaceutical manufacturer aims to use the fresh funds to accelerate its growth and aspires to be among the top five oncology companies in India over the next five years.

By Entrepreneur Staff

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Freepik

Beta Drugs, a vertically integrated oncology-focused pharmaceutical company, has raised INR 117 crore in primary capital from HealthQuad Fund II (HealthQuad), alongside a Singapore-based investment fund and a private wealth management firm, in exchange for a minority stake.

The funding will drive Beta Drugs' global expansion and bolster its operational capabilities. "Their investment and expertise will play a pivotal role in accelerating our growth journey as we strive to position ourselves among the top five oncology companies in India over the next five years," said Rahul Batra, Chairman and Managing Director of Beta Drugs.

Founded in 2005, Beta Drugs boasts a comprehensive portfolio covering chemotherapy, targeted therapies, hormonal treatments, and supportive care.

The company has established a strong domestic presence and expanded into over 46 international markets, with accreditations from regulatory authorities in regions such as Brazil and the EU. Remarkably, Beta Drugs claims that it was the first Indian company to introduce oncology drugs in suspension form, demonstrating its commitment to innovation.

HealthQuad's Partner Ajay Mahipal highlighted the firm's confidence in Beta Drugs' potential: "With its strong manufacturing and R&D capabilities, Beta Drugs is well-positioned to enhance affordability for middle- and lower-income segments while improving access in tier II and III cities. Their new product launches, expanding export markets, and experienced leadership team position the company for substantial growth and value creation."

HealthQuad, a healthcare transformation fund, has a robust portfolio that spans AI, data analytics, diagnostics, and pharma distribution. Its support is expected to amplify Beta Drugs' market impact and product reach.

O3 Capital acted as the exclusive advisor for the transaction, with DSK Legal, Universal Legal, and Desai and Diwanji providing legal counsel.
Entrepreneur Staff

Entrepreneur Staff

Editor

For more than 30 years, Entrepreneur has set the course for success for millions of entrepreneurs and small business owners. We'll teach you the secrets of the winners and give you exactly what you need to lay the groundwork for success.

Most Popular

See all
Business Ideas

70 Small Business Ideas to Start in 2025

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2025.

By Eve Gumpel
Leadership

How Successful Leaders Get More Done in Less Time

The most successful leaders don't work longer; they manage their time with intention. Here's how to master time-blocking, prioritization and delegation to get more done in less time.

By Cyrus Claffey
News and Trends

Kolkata-Based Lab-Grown Diamond Brand Jewelbox Secures USD 3.2 Mn

The startup will primarily use the funds to expand its retail footprint, growing from eight stores to 30 locations by the end of this year.

By Entrepreneur Staff
Science & Technology

How Can Marketers Use ChatGPT? Here Are the Top 11 Uses.

With the recent developments in AI and the popularity of ChatGPT, you may want to integrate AI into your marketing practices. Find out how.

By David James
Marketing

5 Ways ChatGPT Will Impact Digital Marketing

ChatGPT is creating ripples across the digital landscape right now. Here are five ways it can benefit your ads, campaigns and marketing strategies.

By Yasin Altaf
Side Hustle

This Couple Started a Side Hustle to Improve a 'Terribly Made' Bathroom Essential. Now the Business Earns More Than $3 Million a Year.

Michael Fine and Lisa Schulner-Fine launched lifestyle brand Quiet Town in 2016 and have been growing it ever since.

By Amanda Breen